Funding for this research was provided by:
BOSCH+SOHN GmbH u. Co. KG, Jungingen, Germany
RWTH Aachen University
Received: 18 March 2022
Accepted: 21 May 2022
First Online: 15 June 2022
: The authors declare that they have no conflict of interest and there are no competing interests concerning the content of this paper. Joana Schauermann, Svenja Hüsch: none. Bruno Fimm: grants: Institute for Statutory Accident Insurance and Prevention in the Energy, Textile, Electrical, and Media Industry (BGETEM). Christina Haubrich: grants: ParkinsonFonds International Kathrin Reetz: grants: German Federal Ministry of Education and Research (BMBF 01GQ1402, 01DN18022), German Research Foundation (IRTG 2150, ZUK32/1), Alzheimer Forschung Initiative e.V. (AFI 13812, NL-18002CB); honoraria/advisory boards: Lilly, Roche; clinical trial grants: Pfizer, Merck, Minoryx, Biogen, Roche. Jörg B. Schulz: Advisory Board: Biogen, Grifols, Novartis; grant: German Research Foundation, German Ministry of Research and Education. Andrea Maier: Advisory Board: Deutsche EDS Initiative, Deutsche Ehlers-Danlos Selbsthilfe, PoTS und andere Dysautonomien; grants: Takeda Pharmaceuticas, Standing Up to POTS Research Fund, Centogene GmbH.
: The study was approved by the local ethics committee (EK 060/14), registered at clinical trials.gov (NCT03900000), and conducted under the principles of the Declaration of Helsinki. All patients gave written informed consent prior to enrollment.